Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden

被引：2
|
作者：
E. Söreskog
I. Lindberg
J.A. Kanis
K.E. Åkesson
D. Willems
M. Lorentzon
O. Ström
P. Berling
F. Borgström
机构：
[1] Quantify Research,Geriatric Medicine, Department of Internal Medicine and Clinical Nutrition
[2] University of Sheffield,Geriatric Medicine Clinic
[3] Mary MacKillop Institute for Health Research,undefined
[4] Australian Catholic University,undefined
[5] Lund University,undefined
[6] Skåne University Hospital,undefined
[7] UCB Pharma,undefined
[8] Institute of Medicine,undefined
[9] Sahlgrenska Academy,undefined
[10] University of Gothenburg,undefined
[11] Sahlgrenska University Hospital,undefined
[12] Karolinska Institutet,undefined
[13] UCB Pharma,undefined
来源：
Osteoporosis International | 2021年 / 32卷
关键词：
Cost-effectiveness; Economic evaluation; Imminent fracture risk; Markov-microsimulation model; Osteoporosis; Recent fracture;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：585 / 594
页数：9
相关论文
共 50 条
  • [1] Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
    Soreskog, E.
    Lindberg, I.
    Kanis, J. A.
    Akesson, K. E.
    Willems, D.
    Lorentzon, M.
    Strom, O.
    Berling, P.
    Borgstrom, F.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2021, 32 (03) : 585 - 594
  • [2] Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium
    Gielen, Evelien
    Aldven, Martina
    Kanis, John A.
    Borgstrom, Fredrik
    Senior, Emmanuelle
    Willems, Damon
    [J]. OSTEOPOROSIS INTERNATIONAL, 2024, 35 (07) : 1173 - 1183
  • [3] Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada
    Goeree, Ron
    Burke, Natasha
    Jobin, Manon
    Brown, Jacques P.
    Lawrence, Donna
    Stollenwerk, Bjorn
    Willems, Damon
    Johnson, Ben
    [J]. ARCHIVES OF OSTEOPOROSIS, 2022, 17 (01)
  • [4] Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada
    Ron Goeree
    Natasha Burke
    Manon Jobin
    Jacques P. Brown
    Donna Lawrence
    Björn Stollenwerk
    Damon Willems
    Ben Johnson
    [J]. Archives of Osteoporosis, 2022, 17
  • [5] Cost-effectiveness of Romosozumab versus Teriparatide for Severe Postmenopausal Osteoporosis in Japan
    Hagino, Hiroshi
    Tanaka, Kiyoshi
    McClung, Michael
    Silverman, Stuart
    Gandra, Shravanthi
    Charokopou, Mata
    Adachi, Kenji
    Johnson, Benjamin
    Stollenwerk, Bjorn
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2020, 35 : 256 - 256
  • [6] The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden
    Zethraeus, N.
    Strom, O.
    Borgstrom, F.
    Kanis, J. A.
    Jonsson, B.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2008, 19 (06) : 819 - 827
  • [7] The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden
    N. Zethraeus
    O. Ström
    F. Borgström
    J. A. Kanis
    B. Jönsson
    [J]. Osteoporosis International, 2008, 19 : 819 - 827
  • [8] Romosozumab for the treatment of postmenopausal women at high risk of fracture
    Geusens, Piet
    Appelman-Dijkstra, Natasha
    Lems, Willem
    van den Bergh, Joop
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (01) : 11 - 19
  • [9] COST-EFFECTIVENESS OF ABALOPARATIDE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Hiligsmann, M.
    Williams, S. A.
    Fitzpatrick, L. A.
    Reginster, J. -Y.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S50 - S51
  • [10] COST-EFFECTIVENESS OF ABALOPARATIDE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Hansson-Hedblom, A.
    Geale, K.
    Borgstrom, F.
    Johansson, H.
    Fitzpatrick, L.
    Kanis, J. A.
    [J]. VALUE IN HEALTH, 2018, 21 : S197 - S197
12345